ICAAC/IDSA: New Treatment for Cold Sores on Horizon
Topical treatment is effective and without significant side effects
WEDNESDAY, Oct. 29 (HealthDay News) -- A new topical treatment for cold sores is as effective as the leading oral systemic drugs but has fewer safety or toxicity concerns, according to research presented this week at the combined meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America meeting in Washington, D.C.
Mary Flack, M.D., vice president of clinical research at NanoBio and author of the oral presentation, and colleagues conducted a randomized, double-blind, placebo-controlled phase 2b trial of NB-001.
Among the 482 patients studied, lesions treated with the investigational product, NB-001, healed 1.3 days sooner than lesions treated with placebo. NB-001 was well-tolerated, without significant safety concerns or adverse events, and was not systematically absorbed. The authors also note that the delivery system may improve efficacy as well as reduce resistance to the agent.
"The ability of NB-001 to penetrate skin pores and hair follicles is essential to its activity in the dermis and epidermis, where it surrounds and fuses with herpes simplex virus and disrupts the outer envelope of the pathogen," Flack said in a statement. "NB-001 does not compromise tissue integrity, so it is not absorbed into the bloodstream."
Study support was provided by NanoBio.